Kuva Labs has initiated a tender offer to buy all outstanding shares of Lisata Therapeutics at $4.00 per share in cash, with an additional contingent value right (CVR) offering up to $3.00 per share if certain clinical milestones are met. The Lisata board unanimously recommends shareholders accept the offer. The deal values Lisata at a premium to its previous market price and is expected to close in Q3 2026, after which Lisata will be delisted from Nasdaq and become a private company under Kuva. Financing for the offer is not yet secured, and investors are advised to review official documents before deciding.
Aditxt announced a transaction to separate its subsidiary Ignite Proteomics into an independent public company named Ignite Proteomics Inc., while Aditxt remains listed on Nasdaq. Ignite focuses on precision oncology, particularly breast cancer, and ...
FirstService Corporation announced that its subsidiary, Roofing Corp of America (RCA), has acquired Schefers Roofing, a commercial roofing contractor based in Kansas City. This acquisition expands RCA's geographic footprint into the Kansas City marke...
Figure Technology Solutions announced it will acquire Kiavi, an AI-driven lending platform for residential real estate investors, in a $717 million deal. This acquisition will integrate Kiavi's $7 billion annual loan volume into Figure's blockchain-n...
Amazon has expanded its less-than-truckload (LTL) freight service across the U.S., enabling businesses of all sizes to ship palletized freight beyond Amazon's network. This move supports Amazon's broader strategy to grow its third-party logistics bus...
Tecnoglass Inc., a leading manufacturer of high-end aluminum and vinyl windows and architectural glass, announced a quarterly dividend of $0.15 per share for the second quarter of 2026. Shareholders recorded by June 30, 2026, will receive the dividen...
